Ovarian Cancer: Tesaro-FIRSTResearch Question:
Does the drug TSR-042 help the survival of patients with ovarian cancer?
Basic Study Information
Purpose:Study Reference #: IGYO18058
The purpose of this study is to compare the progression-free survival of patients
with Stage III or IV non-mucinous epithelial ovarian cancer treated with platinum-based
therapy, TSR-042, and niraparib to standard-of-care (SOC) platinum-based therapy.
Lead Researcher (Principal Investigator)
Lead Researcher: Richard Moore
Study Contact InformationStudy Coordinator: Laura Mitchell
Phone: (585) 275-7763
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search